The short answer: It can help but not in the way most people think
"We were able to confirm their functions and then look at bigger picture trends, like the relationship of that gene to different kinds of diseases," said Keith Dufault-Thompson, Ph.D., a staff scientist in NLM's Division of Intramural Research (DIR)
GLP-1 showed us that the gut has been acting like an endocrine organ all along, says Dr
Retatrutide extends the same class further as a triple receptor agonist, targeting the GLP-1, GIP, and glucagon receptors together, with the added glucagon activity aimed at boosting energy expenditure alongside appetite suppression
Pancreatitis, gallbladder, thyroid, and kidney concerns remain uncommon, with no clear tirzepatide-specific signal
Two rules apply to all four